Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Lanthanide-Loaded Nanoparticles as Potential Fluorescent and Mass Probes for High-Content Protein Analysis.

Ngamcherdtrakul W, Sangvanich T, Goodyear S, Reda M, Gu S, Castro DJ, Punnakitikashem P, Yantasee W.

Bioengineering (Basel). 2019 Mar 15;6(1). pii: E23. doi: 10.3390/bioengineering6010023.

2.

Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery.

Ngamcherdtrakul W, Sangvanich T, Reda M, Gu S, Bejan D, Yantasee W.

Int J Nanomedicine. 2018 Jul 10;13:4015-4027. doi: 10.2147/IJN.S164393. eCollection 2018.

3.

Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment.

Gu S, Ngamcherdtrakul W, Reda M, Hu Z, Gray JW, Yantasee W.

PLoS One. 2018 Jun 7;13(6):e0198141. doi: 10.1371/journal.pone.0198141. eCollection 2018.

4.

Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, Wood KW, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW.

Breast Cancer Res. 2017 Feb 9;19(1):17. doi: 10.1186/s13058-017-0809-6. No abstract available.

5.

Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.

Morry J, Ngamcherdtrakul W, Gu S, Reda M, Castro DJ, Sangvanich T, Gray JW, Yantasee W.

Mol Cancer Ther. 2017 Apr;16(4):763-772. doi: 10.1158/1535-7163.MCT-16-0644. Epub 2017 Jan 30.

6.

Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.

Hu Z, Mao JH, Curtis C, Huang G, Gu S, Heiser L, Lenburg ME, Korkola JE, Bayani N, Samarajiwa S, Seoane JA, Dane MA, Esch A, Feiler HS, Wang NJ, Hardwicke MA, Laquerre S, Jackson J, W Wood K, Weber B, Spellman PT, Aparicio S, Wooster R, Caldas C, Gray JW.

Breast Cancer Res. 2016 Jul 1;18(1):70. doi: 10.1186/s13058-016-0728-y. Erratum in: Breast Cancer Res. 2017 Feb 9;19(1):17.

7.

Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.

Ngamcherdtrakul W, Castro DJ, Gu S, Morry J, Reda M, Gray JW, Yantasee W.

Cancer Treat Rev. 2016 Apr;45:19-29. doi: 10.1016/j.ctrv.2016.02.005. Epub 2016 Feb 22. Review.

8.

Therapeutic siRNA for drug-resistant HER2-positive breast cancer.

Gu S, Hu Z, Ngamcherdtrakul W, Castro DJ, Morry J, Reda MM, Gray JW, Yantasee W.

Oncotarget. 2016 Mar 22;7(12):14727-41. doi: 10.18632/oncotarget.7409.

9.

Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis.

Morry J, Ngamcherdtrakul W, Gu S, Goodyear SM, Castro DJ, Reda MM, Sangvanich T, Yantasee W.

Biomaterials. 2015 Oct;66:41-52. doi: 10.1016/j.biomaterials.2015.07.005. Epub 2015 Jul 10. Erratum in: Biomaterials. 2016 Jan;74:292.

10.

Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted SiRNA Delivery to HER2+ Breast Cancer.

Ngamcherdtrakul W, Morry J, Gu S, Castro DJ, Goodyear SM, Sangvanich T, Reda MM, Lee R, Mihelic SA, Beckman BL, Hu Z, Gray JW, Yantasee W.

Adv Funct Mater. 2015 May 13;25(18):2646-2659.

11.

Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.

Draz MS, Fang BA, Zhang P, Hu Z, Gu S, Weng KC, Gray JW, Chen FF.

Theranostics. 2014 Jun 11;4(9):872-92. doi: 10.7150/thno.9404. eCollection 2014. Review.

12.

A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma.

Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, Charles RP, Rabinovich BA, Hann B, Dankort D, Spellman PT, Phillips WA, Gray JW, McMahon M.

Cancer Discov. 2012 Aug;2(8):685-93. Epub 2012 May 24.

13.

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.

Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, Feiler HS, Ko AH, Olshen AB, Danenberg KL, Tempero MA, Spellman PT, Hanahan D, Gray JW.

Nat Med. 2011 Apr;17(4):500-3. doi: 10.1038/nm.2344. Epub 2011 Apr 3.

14.

The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer.

Hu Z, Huang G, Sadanandam A, Gu S, Lenburg ME, Pai M, Bayani N, Blakely EA, Gray JW, Mao JH.

Breast Cancer Res. 2010;12(2):R18. doi: 10.1186/bcr2487. Epub 2010 Mar 8.

Supplemental Content

Loading ...
Support Center